Boothbay Fund Management’s Ascendis Pharma A/S ASND Stock Holding History

Boothbay Fund Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,001	Closed	-$994K	–	1958
2025 Q3	$994K	Buy	5,001 +231	+5%	+$43.1K	0.01%	840
2025 Q2	$823K	Buy	+4,770	New	+$777K	0.02%	751
2021 Q3	–	Sell	-2,745	Closed	-$376K	–	1892
2021 Q2	$361K	Sell	2,745 -5,063	-65%	-$675K	0.01%	1170
2021 Q1	$1.01M	Sell	7,808 -3,144	-29%	-$478K	0.04%	593
2020 Q4	$1.83M	Buy	+10,952	New	+$1.81M	0.07%	290
2019 Q2	–	Sell	-23,167	Closed	-$2.77M	–	728
2019 Q1	$2.73M	Buy	+23,167	New	+$2.03M	0.26%	88

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Boothbay Fund Management's ASND Position: Q4 2025 in Review

Boothbay Fund Management sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 5,001 shares — an estimated $994K sold.

Boothbay Fund Management first reported a position in ASND in Q1 2019 and held it in 6 quarters. The position peaked at $2.73M in Q1 2019. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Boothbay Fund Management reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 5,001 Ascendis Pharma A/S shares in Q4 2025, an estimated $994K.
Boothbay Fund Management first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 6 quarters.
Boothbay Fund Management's Ascendis Pharma A/S position peaked at $2.73M in Q1 2019.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.